Clinical trials: Sintilimab
Hepatocellular Carcinoma Non-resectable
Fecal Microbiota Transplantation in Reversing Drug Resistance in Unresectable HCC (TALENP004)
This study aims to evaluate the safety and efficacy of fecal microbiota transplantation (FMT) in reversing drug resistance to the triple therapy regimen in patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- NCT06643533
- Testing
- Fecal Microbiota Transplantation
- Volunteers
- 15 people
- Sponsor
- Fujian Provincial Hospital
High-Risk Resectable NSCLC
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
The proposed study will evaluate the safety and feasibility of preoperative administration nivolumab in patients with high-risk resectable NSCLC, and will facilitate a comprehensive exploratory characterization of the tumor…
- Trial name
- NCT03732664
- Testing
- Nivolumab, Pembrolizumab, Toripalimab, Sintilimab, Sintilimab, Tislelizumab, Durvalumab
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Cancer Metastatic
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal…
- Trial name
- NCT06973343
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Anhui Provincial Cancer Hospital
Hepatocellular Carcinoma Non-resectable
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
The aim of this study is to the efficacy, prognosis, adverse effects, and factors for predicting therapeutic effects and clinical prognosis of combined therapy of transarterial chemoembolization (TACE), Anti-VEGF antibodies or…
- Trial name
- CCGLC-008 (NCT05717738)
- Testing
- TACE, Lenvatinib, Anti-PD-1 monoclonal antibody
- Where
- 4 sites in China
- Volunteers
- 300 people
- Sponsor
- Tongji Hospital
Localized Advanced Rectal Adenocarcinoma
Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer
The standard treatment for locally advanced rectal cancer is neoadjuvant chemoradiotherapy followed by total mesorectal excision.
- Trial name
- NCT06931808
- Testing
- Sintilimab plus Chemotherapy, Intestinal microbiota capsules, Standard Long Course Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Non-small Cell Lung Cancer
Clinical Study of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Non-small Cell Lung Cancer
By exploring the feasibility, effectiveness and safety of neoadjuvant therapy with Sintilimab combined with platinum-containing chemotherapy in patients with resectable Stage ⅡB-ⅢA NSCLC, we will provide new treatment options and…
- Trial name
- NCT05170581
- Testing
- Sintilimab Combined with Platinum-containing Chemotherapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The Second Affiliated Hospital of Shandong First Medical University
Gastric Adenocarcinoma, GEJ Adenocarcinoma
Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer
This study was designed to explore the efficacy and safety of fruquintinib combined with PD-1 inhibitors as first-line maintenance therapy for advanced HER-2 Negative Gastric Cancer.
- Conditions
- Gastric Adenocarcinoma, GEJ Adenocarcinoma, First-line Therapy, Maintenance Therapy
- Trial name
- NCT06888037
- Testing
- Initial treatment: PD-1+ Oxaliplatin-based chemotherapy (CAPOX/SOX/FOLFOX）, Maintenance treatment (after 3 months): fruquintinib+PD-1
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Ruijin Hospital
Non-Small Cell Lung Cancer
Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction
This study aimed to evaluate the efficacy and safety of bronchoscopic cryoablation combined with sintilimab plus platinum-based chemotherapy as First-line Treatment for locally advanced or metastatic NSCLC with central airway…
- Trial name
- Example (NCT06604351)
- Testing
- Sintilimab, Nab-Paclitaxel, and Carboplatin
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Hunan Province Tumor Hospital
Stomach Neoplasms, Esophagogastric Junction Disorder
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage.
- Conditions
- Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy
- Trial name
- NeoRacing (NCT05161572)
- Testing
- Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fudan University
Recurrent Glioblastoma
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination with Bevacizumab and Temozolomide in subjects with recurrent glioblastoma.
- Trial name
- NCT05638451
- Testing
- Sintilimab plus Bevacizumab and Temozolomide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
Cervical Carcinoma
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
For locally advanced cervical cancer, there are two main treatment options: One is radical chemoradiotherapy (a combination of radiotherapy and chemotherapy aimed at curing the disease).
- Trial name
- NCT07088731
- Testing
- Sintilimab, Concurrent chemo-radiotherapy
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
- Trial name
- NCT06084897
- Testing
- TP (Paclitaxel with cisplatin or carboplatin) or PF (Fluoropyrimidine with cisplatin or carboplatin) regimen depended on investigator's choice., PD-1 inhibitor, Consolidation Radiation
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced HCC, Systemic Therapy
Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC
In China, primary hepatocellular carcinoma (HCC) has high morbidity and mortality, imposing a heavy burden on the public. Surgical resection is an effective treatment, but as HCC is often latent, less than 30% of patients are…
- Conditions
- Advanced HCC, Systemic Therapy, Chemotherapy, Immunotherapy
- Trial name
- T+I+XELOX (NCT06818097)
- Testing
- TKI, anti PD-1, XELOX chemotherapy
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Non Small Cell Lung Cancer
A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC
The purpose of this study is to determine the feasibility and evaluate the safety of delivering chemotherapy, the usual approach to non-small cell lung cancer, in combination with Sintilimab (PD-1 antibody), followed by adjuvant…
- Trial name
- NCT04840290
- Testing
- Biological: Sintilimab Drug: Cisplatin Drug: Paclitaxel for Injection (Albumin Bound) Drug: Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tang-Du Hospital
Non-small Cell Lung Cancer Stage III
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
Patients with stage III non-small-cell lung cancer initially evaluated as unresectable are selected for the program, who are remained unresectable after 2-4 cycles of conversion chemotherapy combined with immune checkpoint…
- Trial name
- NCT06031597
- Testing
- radiotherapy, Platinum-Based Drug, Immunotherapy
- Volunteers
- 105 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Advanced Colorectal Cancer
Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study
A phase II study to assess the efficacy and safety of Surufatinib combined with Sintilimab as a second-line treatment in patients with advanced MSS-Type CRC.
- Trial name
- NCT04764006
- Testing
- Surufatinib
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Fujian Cancer Hospital
Non-Small Cell Lung Cancer
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients
To investigate the efficacy and safety of sindilizumab combined with platinum-containing dual chemotherapy in first-line treatment of elderly patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT06883136
- Testing
- Sintilimab+Cis-platinum/Carboplatin with Pemetrexed or Gemcitabine
- Where
- 2 sites in China
- Volunteers
- 43 people
- Sponsor
- Qianfoshan Hospital
Metastasis Colorectal Cancer
Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer
This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer
- Trial name
- NCT04179084
- Testing
- fruquintinib, Sintilimab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese PLA General Hospital
Peritoneal Mesothelioma
PTC-Guided Therapy for Peritoneal Mesothelioma
Official Title: A Study of Key Parameters and Mechanisms in Personalized Diagnosis and Treatment Using Tumor Models Why is this study being done? This research study is for adults with a type of cancer called Malignant Peritoneal…
- Trial name
- NCT07330271
- Testing
- PTC guided individualized treatment, Standard chemotherapy regimens
- Where
- China
- Volunteers
- 347 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital